Connect with us

Technology

Seegene’s CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation

Published

on

Seegene previews a concept video of CURECATM at ESCMID Global 2025, ahead of its anticipated debut in JulyWith a fully modular design, CURECATM introduces a bold vision for automating pre-treatment across diverse PCR specimen typesDeveloped for future integration into unattended workflows and adaptable laboratory settings

SEOUL, South Korea, May 2, 2025 /PRNewswire/ — Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, has attracted strong interest after the company presented a conceptual video of its CURECATM at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria. 

Industry professionals recognized CURECATM as a promising advancement in automating the entire PCR diagnostic workflow — from primary sample handling to result analysis. In response to the interest received, Seegene provided additional opportunities to showcase the solution at the ESCMID Global 2025.

More than 2,300 attendees — including dignitaries from Italy, Spain, Germany, France, and Canada — visited Seegene’s booth to view the conceptual video introducing the CURECATM. “It was evident that the Seegene booth attracted considerable attention at ESCMID,” said one professional from academia.

Experts Recognize CURECATM as a Game Changer in Molecular Testing Automation

The CURECATM is designed to automate the entire PCR diagnostic process. It can handle various specimen types required in the pre-treatment stage in MDx – such as stool, urine, blood, and sputum—as well as perform the complete PCR testing workflow following sample loading. 

The following are select comments from industry professionals who previewed Seegene’s CURECATM at ESCMID Global 2025:

“I hold high expectations for the fully automated PCR molecular diagnostics, as CURECATM not only eliminates human error inherent in manual processes but also enables efficient testing without time or workforce constraints.”

“We often encounter specimen types that require careful and time-consuming manual pre-processing. A system that can automate this step could represent a true paradigm shift. This level of automation is transformative – a real game changer – and unlike any existing solution. I eagerly await its launch.”

“If paired with our in-house diagnostic tool kits, CURECATM could offer a complete synergy. I hope CURECATM will be accessible to small and mid-sized facilities.”

“I’m planning to attend ADLM 2025 in Chicago in July to see the actual device and explore potential collaborations.”

Customizable Pre-Treatment System Offers Versatility for Future Laboratory Automation

The first component of CURECATM is the Customizable Pre-treatment System (CPS). The CPS is designed to automate the loading of primary sample tubes and operate pre-treatment processing.

“The CPS is a modular, automated system intended to streamline pre-treatment processing across diverse diagnostic fields including molecular diagnostics such as PCR, as well as clinical chemistry and immunology assays,” said Young-Seag Baeg, Head of Strategy and Planning at Seegene.

Numerous healthcare (or laboratory) professionals at ESCMID Global 2025 noted that the conceptual video of CURECATM showcased the potential of fully automated diagnostic laboratories capable of managing complex workflows associated with pre-treatment. In particular, there was consensus among participants that the CPS, which automates specimen preprocessing, is positioned to bring a significant advancement in in vitro diagnostics as it addresses limitations associated with existing manual procedures that are dependent on trained laboratory professionals.

“The turnaround time (TAT) is expected to improve with CURECATM as the integrated software is capable of adjusting workflows based on reporting deadlines,” said a director of a laboratory in Spain. “In particular, for sexually transmitted infections (STIs), the CPS will markedly enhance daily laboratory operations. The processing of specimens for STIs involves manual handling of multiple sample tubes, which contributes to operator fatigue. The adoption of the CPS has the potential to be transformational in streamlining routine operations.” 

Modular and Configurable Solution Design for Tailored Diagnostics

Following specimen preprocessing, molecular diagnostics typically involve nucleic acid extraction, PCR setup and amplification, and analysis of results. For specimens that do not need preprocessing, Seegene offers the Primary Sample Aliquot System (PAS) as an alternative to the CPS. PAS is designed to allow direct loading and dispensing of primary samples, helping to simplify the workflow. Seegene is pursuing the integration of PAS with a fully automated PCR process through a modular solution concept called CEFA (Customizable & Expandable Full Automation), intended to support diverse laboratory needs with greater flexibility.

Seegene aims to leverage the modular architecture of CURECATM to support a wide range of diagnostic applications. “CURECATM can be deployed as a comprehensive system or as individual modules—CPS, PAS, and CEFA—configured independently or in combination to accommodate diverse operational needs,” said Baeg.

Optimizing Lab Workflows Through Space-Saving Design

Another key advantage of the CURECATM’s modular architecture is that it is designed to adapt to different laboratory spaces and layouts. Its flexible design is intended to allow labs to configure the system according to their specific needs, which Seegene sees as essential for enhancing operational efficiency.

Laboratory professionals at ESCMID 2025 shared the following perspectives:

“The ability to configure a system to meet specific spatial and operational needs of individual laboratories represents a novel and highly compelling approach.”

“We expect such flexibility will make it possible to implement workflows that deliver high-quality results with minimal reliance on standardized laboratory configurations and staffing resources.”

“The enthusiastic global response to our concept video and vision for CURECATM demonstrate the strong demand for next-generation diagnostic solutions,” said Jong-Yoon Chun, CEO of Seegene. “We believe CURECATM has the potential to catalyze meaningful change in the global PCR diagnostics landscape.”

Please Note:

The comments included in this press release are based on actual interviews and on-site discussions. However, in accordance with requests to protect the privacy of the individuals interviewed, all names have been pseudonimized.

About Seegene

Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene’s syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information.

Visit: Seegene.com and follow linkedin.com/company/seegene-inc

Technology-sharing Initiative

The technology-sharing initiative aims to globally share Seegene’s advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. The initiative’s ultimate vision is to create “a world free from diseases”—a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness.

 

 

Photo – https://mma.prnewswire.com/media/2677171/PHOTO_1.jpg

Photo – https://mma.prnewswire.com/media/2677172/Photo_2_1__Seegene_presented_a_concept_video_of_its_CURECA__system_at_ESCMID_2025__held_April_11_15.jpg

Photo – https://mma.prnewswire.com/media/2677173/Photo_2_2__Seegene_s_CURECA__concept_video_drew_interest_from_attendees_during_ESCMID_2025__held_Apr.jpg

Logo – https://mma.prnewswire.com/media/1357790/5295869/Seegene_logo_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/seegenes-curecatm-emerges-as-a-potential-game-changer-in-end-to-end-pcr-automation-302444934.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

CNN to bring its Global Perspectives events series to Bangkok

Published

on

By

Conversations to be led by CNN journalists including Dr. Sanjay Gupta, Richard Quest and Kristie Lu Stout

HONG KONG, April 21, 2026 /PRNewswire/ — CNN will hold the inaugural Asia chapter of its Global Perspectives events franchise in Bangkok, Thailand, on 14 October 2026, reinforcing the network’s commitment to convene global leaders and fostering dialogue on the critical issues shaping international business, policy and economic development.

CNN will bring together dignitaries, visionaries, political and business leaders for Global Perspectives: In Bangkok, to explore big ideas, bold leadership and the dynamic economies at the forefront of global transformation. On-stage conversations will be led by CNN’s esteemed anchors and correspondents, including Dr. Sanjay Gupta, Richard Quest, Kristie Lu Stout, Will Ripley and Hanako Montgomery, with editorial content and news-making interviews from the event featured across CNN platforms.

Expanding the Global Perspectives series with this Bangkok edition underscores CNN’s long-standing engagement in Asia. As a historic economic and cultural crossroads, Bangkok sits at the intersection of global economic dynamism, regional influence and vibrant cultural energy. The event will take place as global leaders, investors and policymakers gather in the city for the International Monetary Fund and World Bank Group Annual Meetings, creating an exclusive platform for CNN to examine a world in transition and the forces reshaping power and influence.

Ellana Lee, Group SVP, GM APAC, & Global Head of Productions at CNN, said: “Global Perspectives: In Bangkok will reflect CNN’s deep commitment to Asia and will aim to foster conversations that matter most on the global stage. At a time of rapid transformation, this event will bring together influential voices to examine the ideas, opportunities and challenges shaping the region and the world.” 

James Hunt, SVP, Head of Client Solutions & Business Lead, Global Perspectives, CNN International Commercial said: “Global Perspectives provides a unique platform for leaders and partners to engage in meaningful dialogue and connect with the forces driving global change. Hosting the event in Bangkok creates new opportunities for brand partners and sponsors to be associated with important conversations about collaboration, insight and impact at the heart of one of the world’s most dynamic regions.”

Expanding its events franchise by holding Global Perspectives: In Bangkok builds on CNN’s long-standing presence in Asia which includes a network of bureaus and correspondents across Hong Kong, Beijing, Bangkok, Taiwan, Seoul, Tokyo, New Delhi and Islamabad.

Global Perspectives is an invitation-only gathering for international decision-makers and influential leaders from across industries, including technology, finance, investment, trade, geopolitics, healthcare, media, entertainment and more. The event will be attended by heads of state, regional and global leaders, and participants can expect to form meaningful connections that will last well beyond the event itself. Global Perspectives will be hosted at The Ritz-Carlton, Bangkok. 

Further details on speakers and programming will be announced in due course. People interested in attending Global Perspectives: In Bangkok can register their interest at: https://cnnicevents.cnn.com/gpbangkok/prl

About CNN Worldwide

CNN Worldwide is the most honored brand in cable news, reaching more individuals through television, streaming and online than any other cable news organization in the United States. Globally, people across the world can watch CNN International, which is widely distributed in over 200 countries and territories. CNN Digital is the #1 online news destination, with more unique visitors than any other news source. HBO Max, Warner Bros. Discovery’s streaming platform, features CNN Max, a 24/7 streaming news offering available to subscribers alongside expanded access to News content and CNN Originals. CNN’s award-winning portfolio includes non-scripted programming from CNN Original Series and CNN Films for broadcast, streaming and distribution across multiple platforms. CNN programming can be found on CNN, CNN International and CNN en Español channels, via CNN Max and the CNN Originals hub on discovery+ and via pay TV subscription on CNN.com, CNN apps and cable operator platforms. Additionally, CNN Newsource is the world’s most extensively utilized news service partnering with over 1,000 local and international news organizations around the world. CNN is a division of Warner Bros. Discovery.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cnn-to-bring-its-global-perspectives-events-series-to-bangkok-302748000.html

SOURCE CNN International

Continue Reading

Technology

Quality Executive Partners, Inc.® Announces Exclusive Partnership with Vi’eNnI® Training and Consulting LLP to Accelerate Workforce Development in India’s Huge Pharmaceutical Sector with Virtuosi®

Published

on

By

ATLANTA and BENGALURU, India, April 21, 2026 /PRNewswire/ — Quality Executive Partners, Inc.® (QxP), a global leader in pharmaceutical quality, workforce development, regulatory compliance, and manufacturing consulting, today announced an exclusive strategic partnership with Vi’eNnI® Training and Consulting LLP to introduce and scale Virtuosi® across the Indian biopharmaceutical market.

Virtuosi helps biopharmaceutical manufacturers to solve one of their most critical operational challenges—the readiness of the workforce to perform in high-risk, high-complexity GMP environments—by building and sustaining operational capability across the employee lifecycle.

Under this agreement, Vienni will be QxP’s exclusive partner for Virtuosi in India, leading market engagement, client identification, and commercial activities.

Vi’eNnI® TRAINING & CONSULTING LLP: Enabling Scalable Training Excellence Across India

Vi’eNnI® is a recognized leader in pharmaceutical training and capability development in India, with a strong track record in GMP education, regulatory compliance, and industry engagement. Vi’eNnI® through its association with Eduoriens Skill Development LLP and professional bodies such as Parenteral Drug Association (PDA) India, Vienni operates at the center of India’s pharmaceutical training and compliance ecosystem.

With this established network, operational credibility, and relationships across India’s leading pharmaceutical manufacturers, Vienni is uniquely positioned to drive the adoption of Virtuosi at scale across the Indian market.

“This alliance is intended to deepen, enrich, and embed the field of training. The advantage of this collaboration is expected to make learning stick, with recall much higher when a participant leaves the learning zone,” said Vishal Sharma, Co-Founder Director, Vi’eNnI® TRAINING & CONSULTING LLP

“This marks the beginning of driving innovation and shaping outcomes that matter. Together, we forge a partnership that speaks the language of impact, influence, and enduring progress for teaching-learning & implementation,” said Ivy Louis, Founder Director, Vi’eNnI® TRAINING & CONSULTING LLP

“Vi’eNnI®’s mission is to empower doers to excel in their craft. This association with QxP for Virtuosi marks a pivotal step in advancing workforce capability and highlighting the strategic value of immersive training in India. We are proud to continue driving this mission forward.”

“We are honored to partner with Vi’eNnI® , a highly respected organization with deep roots in the Indian pharmaceutical industry,” said Crystal Mersh, Chief Executive Officer of Quality Executive Partners, Inc. “Together, we are enabling broader access to Virtuosi in a way that allows clients to build and sustain the knowledge, skills, and behaviors required to perform under real operating conditions. This embeds compliance and capability into daily execution in order to deliver high quality medicines to patients around the world.”

Virtuosi by QxP: Advancing Workforce Capability in India’s Globally Critical Pharmaceutical Hubs

India is one of the most critical pharmaceutical manufacturing markets globally and is poised for significant growth in the coming years, particularly across biologics, biosimilars, and advanced therapies. As manufacturers expand into more complex product categories and face increasing scrutiny from global regulatory agencies—including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) —the ability to rapidly build, standardize, and sustain a high-performing, inspection-ready workforce has become a strategic priority.

cGMP experts at QxP created Virtuosi to address this exact challenge. Virtuosi is an immersive workforce readiness program accredited by the International Accreditors for Continuing Education and Training (IACET), aligning with globally recognized standards for continuing education and distinguishing it as the only virtual reality–based training program to achieve such accreditation.

Combining virtual reality interactive experiences with digital course content, Virtuosi enables professionals to practice critical manufacturing and quality processes—such as aseptic operations, microbiology, and advanced therapies—in realistic, risk-free environments. The platform includes over 100 hours of education, 56 technical courses, and 20 immersive VR experiences, and is available in seven languages—English, French, German, Italian, Mandarin, Spanish, and Swedish—to support global workforce standardization. Virtuosi helps organizations reduce human error, accelerate time to competency, and improve compliance and operational performance across global pharmaceutical operations.

By shifting training from passive instruction to experiential learning, Virtuosi helps reduce time to competency and human error, improve inspection readiness, and drive measurable quality outcomes which translates directly to revenue protection and growth. This partnership strengthens not only the competitiveness of individual organizations, but also the long-term resilience, regulatory standing, and global leadership of India’s pharmaceutical sector.

About Quality Executive Partners, Inc.® (QxP)

Quality Executive Partners, Inc. (QxP) is a premium CGMP consulting firm focused on solving complex operational and regulatory challenges in pharmaceutical manufacturing. QxP services pharmaceutical manufactures and CDMOs globally across all major modalities – OTC, oral solid dosage, sterile, biologics, ATMPs, clinical-stage manufacturing, and combination products. We support clients throughout the product lifecycle, including clinical operations, commercial readiness, regulatory strategy, quality transformations, and remediation. Through our ‘Teach and Do®’ model, QxP embeds senior GMP experts / former regulators into day-to-day operations to execute alongside client teams and build internal capability. This model ensures solutions are effective in practice, sustainable, and directly reduce operational risk. .

About Vi’eNnI®

Vi’eNnI® Training and Consulting LLP is a pharmaceutical training and consulting organization based in Bengaluru, India, focused on advancing workforce capability, regulatory compliance, and operational excellence across the life sciences sector, for the past 16 years. The company delivers targeted training and consulting services across GMP, quality systems, aseptic processing, microbiology, and inspection readiness, competency and culture building initiatives, helping organizations strengthen performance, consolidate efficiency and achieve sustainable compliance. Known for its practical, implementation-focused approach, Vi’eNnI® enables pharmaceutical and biotechnology companies to translate training into measurable improvements on the shop floor, supporting continuous improvement and long-term capability development across India’s pharmaceutical industry with a variety of options and tools.

Media Contact (Global)
Robin Mersh
SVP, Virtuosi Sales
Quality Executive Partners, Inc.
Email: RobinMersh@QualityExecutivePartners.com
Phone: (+1) 678-496-7503

Media Contact (India)
Ivy Louis
Founder-Director
Vi’eNnI® Training and Consulting LLP
Email: Ivy_louis@vienni.com
Phone: +91 9986821045
WhatsApp: +91 9986821045

Vi’eNnI® & Virtuosi® are registered trademarks for VIENNI & Quality Executive Partners, Inc., respectively.

Logo – https://mma.prnewswire.com/media/2790799/5926395/Virtuosi_Logo.jpg

View original content:https://www.prnewswire.com/in/news-releases/quality-executive-partners-inc-announces-exclusive-partnership-with-vienni-training-and-consulting-llp-to-accelerate-workforce-development-in-indias-huge-pharmaceutical-sector-with-virtuosi-302748013.html

Continue Reading

Technology

Tuniu Corporation Files Its Annual Report on Form 20-F

Published

on

By

NANJING, China, April 20, 2026 /PRNewswire/ — Tuniu Corporation (NASDAQ:TOUR) (“Tuniu” or the “Company”), a leading online leisure travel company in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission on April 20, 2026, U.S. Eastern Time. The annual report can be accessed on the Company’s investor relations website at http://ir.tuniu.com or the SEC’s website at www.sec.gov. The Company will provide a copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to the Investor Relations Department at 12th floor, building 6-A, Juhuiyuan, No.108 Xuanwudadao, Xuanwu District, Nanjing, Jiangsu Province 210023, The People’s Republic of China.

About Tuniu Corporation

Tuniu (Nasdaq: TOUR) is a leading online leisure travel company in China that offers integrated travel service with a large selection of packaged tours, including organized and self-guided tours, as well as travel-related services for leisure travelers through its website tuniu.com and mobile platform. Tuniu provides one-stop leisure travel solutions and a compelling customer experience through its online platform and offline service network, including a dedicated team of professional customer service representatives, 24/7 call centers, extensive networks of offline retail stores and self-operated local tour operators. For more information, please visit http://ir.tuniu.com.

View original content:https://www.prnewswire.com/news-releases/tuniu-corporation-files-its-annual-report-on-form-20-f-302747995.html

SOURCE Tuniu Corporation

Continue Reading

Trending